DE69837170D1 - Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen - Google Patents

Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen

Info

Publication number
DE69837170D1
DE69837170D1 DE69837170T DE69837170T DE69837170D1 DE 69837170 D1 DE69837170 D1 DE 69837170D1 DE 69837170 T DE69837170 T DE 69837170T DE 69837170 T DE69837170 T DE 69837170T DE 69837170 D1 DE69837170 D1 DE 69837170D1
Authority
DE
Germany
Prior art keywords
unprotected
cysteine
solid
aqueous solutions
chemical ligation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69837170T
Other languages
English (en)
Other versions
DE69837170T2 (de
Inventor
Lynne Canne
Stephen B H Kent
Reyna Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Gryphon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Therapeutics Inc filed Critical Gryphon Therapeutics Inc
Publication of DE69837170D1 publication Critical patent/DE69837170D1/de
Application granted granted Critical
Publication of DE69837170T2 publication Critical patent/DE69837170T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
DE69837170T 1997-06-13 1998-06-12 Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen Expired - Fee Related DE69837170T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4955397P 1997-06-13 1997-06-13
US49553P 1997-06-13

Publications (2)

Publication Number Publication Date
DE69837170D1 true DE69837170D1 (de) 2007-04-05
DE69837170T2 DE69837170T2 (de) 2007-11-22

Family

ID=21960431

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69828287T Expired - Fee Related DE69828287T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
DE69837170T Expired - Fee Related DE69837170T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69828287T Expired - Fee Related DE69828287T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Country Status (9)

Country Link
US (4) US6326468B1 (de)
EP (1) EP1001968B1 (de)
JP (1) JP2002505672A (de)
AT (2) ATE354584T1 (de)
AU (1) AU745094B2 (de)
CA (1) CA2292724A1 (de)
DE (2) DE69828287T2 (de)
ES (2) ES2235336T3 (de)
WO (1) WO1998056807A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
EP1001968B1 (de) * 1997-06-13 2004-12-22 Gryphon Therapeutics, Inc. Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
US6844161B2 (en) * 1997-09-04 2005-01-18 Gryphon Therapeutics, Inc. Modular protein libraries and methods of preparation
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US7001745B1 (en) * 1998-09-30 2006-02-21 New England Biolabs, Inc. Intein mediated peptide ligation
EP1159289A1 (de) * 1999-03-11 2001-12-05 Gryphon Sciences Chemische synthese und verwendung von löslichen membranproteinrezeptordomänen
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US20020155455A1 (en) * 2000-08-11 2002-10-24 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US6977292B2 (en) * 2000-09-01 2005-12-20 Gryphon Therapeutics Nucleophile-stable thioester generating compounds, methods of production and use
DK1353941T3 (da) * 2001-01-22 2013-06-17 Sangamo Biosciences Inc Modificerede zinkfingerbindingsproteiner
JP4408628B2 (ja) * 2001-03-09 2010-02-03 ボストン プローブス，インコーポレイテッド 組み合わせオリゴマーならびにそれらの調製のためのライブラリーに適する、方法、キット、および組成物
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
CN101724075B (zh) 2001-10-10 2014-04-30 诺和诺德公司 肽的重构和糖缀合
EP2298354B1 (de) 2001-10-10 2014-03-19 ratiopharm GmbH Neumodulierung und Glykokonjugation von Interferon-beta
ATE458745T1 (de) * 2002-06-10 2010-03-15 Amylin Pharmaceuticals Inc Nachspaltige sulfurentschützung zur konvergenten proteinherstellung beim verfahren von chemischer ligation
DK1450786T3 (da) * 2002-06-29 2006-04-18 Aquanova Ger Solubilisate Tech Isoflavonkoncentrater samt fremgangsmåde til fremstilling deraf
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7981862B2 (en) 2003-08-19 2011-07-19 Biosurface Engineering Technologies, Inc. Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
EP1578962A4 (de) * 2002-12-11 2007-03-14 New England Biolabs Inc Träger-ligand-fusionen und verwendungen davon
EP1616003A4 (de) * 2002-12-30 2007-06-20 Gryphon Therapeutics Inc Wasserlösliche thioester- und selenoesterverbindungen sowie verfahren zur herstellung und verwendung davon
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
ATE497783T1 (de) * 2003-05-06 2011-02-15 Syntonix Pharmaceuticals Inc Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
WO2004105685A2 (en) * 2003-05-22 2004-12-09 Gryphon Therapeutics, Inc. Displaceable linker solid phase chemical ligation
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
JP4895826B2 (ja) * 2004-02-20 2012-03-14 バイオサーフェス エンジニアリング テクノロジーズ，インク． 骨形成蛋白−２の正のモジュレーター
CA2563502A1 (en) 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
US7872096B2 (en) * 2004-05-24 2011-01-18 Rigel Pharmaceuticals, Inc. Methods for cyclizing synthetic polymers
ATE439140T1 (de) 2005-03-31 2009-08-15 Amylin Pharmaceuticals Inc Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
WO2007100358A2 (en) * 2005-10-07 2007-09-07 University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
US20090118271A1 (en) * 2005-10-19 2009-05-07 Chugai Seiyaku Kabushiki Kaisha Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
EP2120985B1 (de) 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 Peptide zur Verwendung bei der Behandlung Psychotischer- und Angsterkrankungen
ES2441197T3 (es) * 2007-08-28 2014-02-03 Ipsen Pharma S.A.S. Método para la síntesis química de polipéptidos y proteínas
CA2790343A1 (en) * 2010-02-18 2011-08-25 Advanced Proteome Therapeutics Inc. Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
MX345245B (es) 2010-09-28 2017-01-23 Amylin Pharmaceuticals Llc Polipeptidos manipulados que tienen duracion de accion incrementada.
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
US20140256621A1 (en) 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
FR2981352B1 (fr) * 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
US9545449B2 (en) 2012-05-11 2017-01-17 Advanced Proteone Therapeutics Inc. Site-specific labeling and targeted delivery of proteins for the treatment of cancer
EP2852619A4 (de) 2012-05-21 2016-04-27 Massachusetts Inst Technology Translokation nichtnatürlicher chemischer stoffe durch vor milzbrand schützende antigenporen
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
US11273176B2 (en) 2016-03-02 2022-03-15 The Brigham And Women's Hospital, Inc. Use of PLA2G5-deficient suppressive macrophages in suppression of inflammation
AU2018228182B2 (en) * 2017-03-02 2024-04-11 Glytech, Inc. Production method for amino-acid polymer
JP2022508558A (ja) 2018-10-01 2022-01-19 ユニベルシテ ド ジュネーヴ 生物学的分析に適した複数のポリペプチドバリアントを生成する方法
WO2020110330A1 (ja) * 2018-11-30 2020-06-04 株式会社糖鎖工学研究所 ペプチドチオエステル、ペプチドの新規製造方法
JP2022552194A (ja) 2019-10-10 2022-12-15 １８５９，インク． マイクロ流体スクリーニングのための方法およびシステム
US20210230218A1 (en) * 2019-10-23 2021-07-29 Mabplex International, Ltd. Oligopeptide linker intermediate and preparation method thereof
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064940A (en) * 1988-05-11 1991-11-12 Protein Technologies, Inc. Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
MX9708500A (es) 1995-05-04 1998-02-28 Scripps Research Inst Sintesis de proteinas mediante ligacion quimica nativa.
JP4358307B2 (ja) * 1996-12-24 2009-11-04 ザ スクリップス リサーチ インスティテュート 一般的化学結合
EP1001968B1 (de) * 1997-06-13 2004-12-22 Gryphon Therapeutics, Inc. Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
US6329468B1 (en) * 2000-01-21 2001-12-11 Bostik Findley, Inc. Hot melt adhesive based on semicrystalline flexible polyolefins

Also Published As

Publication number Publication date
US6326468B1 (en) 2001-12-04
US20050209440A1 (en) 2005-09-22
AU745094B2 (en) 2002-03-14
ES2235336T3 (es) 2005-07-01
ATE285415T1 (de) 2005-01-15
US7094871B2 (en) 2006-08-22
ES2282788T3 (es) 2007-10-16
WO1998056807A1 (en) 1998-12-17
US20020169282A1 (en) 2002-11-14
ATE354584T1 (de) 2007-03-15
JP2002505672A (ja) 2002-02-19
EP1001968A1 (de) 2000-05-24
CA2292724A1 (en) 1998-12-17
DE69837170T2 (de) 2007-11-22
US20020132975A1 (en) 2002-09-19
US7030217B2 (en) 2006-04-18
DE69828287D1 (de) 2005-01-27
DE69828287T2 (de) 2005-12-15
AU8069598A (en) 1998-12-30
EP1001968B1 (de) 2004-12-22

Similar Documents

Publication Publication Date Title
DE69837170D1 (de) Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
Han et al. Ion trap collisional activation of c and z• ions formed via gas-phase ion/ion electron-transfer dissociation
NZ527053A (en) Modified amyloid precursor protein polynucleotides and polypeptides
NO993341L (no) Analoger av paratyroidhormon
WO2003057845A3 (en) Automated systems and methods for analysis of protein post-translational modification
CA2303758A1 (en) Improved methods of identifying peptides and proteins by mass spectrometry
GB2330450B (en) Chemical ionization source for mass spectrometry
WO2003074992A3 (en) Phosphorylated proteins and uses related thereto
DK0914331T3 (da) Neuroaktive peptider
NO970740L (no) Glutamat reseptor
EP0699753A3 (de) Transportprotein, das den Transport von kationischen Xenobiotika und/oder Pharmaka bewirkt, dafür kodierende DNA-Sequenzen und deren Verwendung
Miskevich et al. Metal complexes as artificial proteases in proteomics: A palladium (II) complex cleaves various proteins in solutions containing detergents
AUPR378001A0 (en) Protein chip
GB9816514D0 (en) Novel method
WO2002037121A3 (en) Detection of modified amino acids by mass spectrometry
AU2002322506A1 (en) Non-affinity based isotope tagged peptides and methods for using the same
Baker et al. Tandem mass spectrometry of model peptides modified with trans-2-hexenal, a product of lipid peroxidation
Wang et al. Screening combinatorial libraries for optimal enzyme substrates by mass spectrometry
NO982227D0 (no) Urogenitalcarcinom-TPL komplekspeptider og antistoffer derav
Ramachnandran et al. Conformation of peptide chains containing both L-& D-residues. I. Helical structures with alternating L-& D-residues with special reference to the LD-ribbon & the LD-helices
WO2003087805A3 (en) Method for efficiently computing the mass of modified peptides for mass spectrometry data-based identification
Andrews et al. Large-scale protein mapping using infrequent cleavage reagents, LD TOF MS, and ES MS
ES2166188T3 (es) Procedimiento para la conmutacion de etapas de transaccion.
EP1518862A3 (de) Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
NO960041D0 (no) Hemoregulatoriske penta- eller heksapeptider

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AMYLIN PHARMACEUTICALS, INC., SAN DIEGO, CALIF, US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee